MetaCap

Actuate Therapeutics Inc. (ACTU)

NASDAQ: ACTUHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.2253+0.0115 (+5.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ACTU stock chart

Technical analysis

Key statistics

All statistics
Market cap
$13.60M
EPS (TTM)
-$0.76
52-week range
0.174 – 7.90
Day range
0.20 – 0.2475
Volume / Avg
629.80K / 807.24K
Beta
—

52-week range

$0.174$7.90

ACTU stock today

Actuate Therapeutics (ACTU) closed at $0.2253 on Nov 20, up 5.38% (+$0.0115), versus the S&P 500's 3.70% decline. Shares are 97.1% below their 52-week high of $7.90, set on Dec 10, 2025 and 29.5% above the 52-week low of $0.174, near the bottom of the past year's range. ACTU is down 96.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 96.4%.

Actuate Therapeutics has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Actuate Therapeutics

Company profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel M. Schmitt
Headquarters
Fort Worth, TX
Employees
12
IPO year
2024

Financial highlights

Full financials

Actuate Therapeutics reported a net loss of $22.2 million, compared with a loss of $27.3 million a year earlier. Diluted earnings per share came in at -$1.06.

Actuate Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-22.23M$-27.29M$-24.74M
EPS (diluted)$-1.06$-3.26$-17.24

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$11.68+5084.20%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $15.05

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.14 vs $-0.18
Surprise
+22.22%

ACTU news

All ACTU news

Actuate Therapeutics peers

Health Care sector
ACTU peer companies
CompanyPrice% ChgMarket capCompare
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs ACTU
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs ACTU
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs ACTU
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs ACTU
NEUPNeuphoria Therapeutics Inc.2.35+1.29%$12.72Mvs ACTU
MCRBSeres Therapeutics Inc.1.24-6.77%$12.64Mvs ACTU
ALLRAllarity Therapeutics Inc.0.785-9.25%$12.56Mvs ACTU
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs ACTU

Indexes, lists and sector

Actuate Therapeutics stock FAQ

What is Actuate Therapeutics's stock price today?

ACTU last traded at $0.2253 as of Nov 20, 4:00 PM EST, up 5.38% on the day. Prices are delayed at least 15 minutes.

Who is Actuate Therapeutics's CEO?

Mr. Daniel M. Schmitt is the chief executive officer of Actuate Therapeutics Inc., which has about 12 employees.

What is the ACTU 52-week high?

The 52-week high for ACTU is $7.90 and the 52-week low is $0.174. The stock is currently 97.1% below its high.

Compare ACTU